Drug Profile
Research programme: glutamate modulating agents - Biohaven Pharmaceuticals
Latest Information Update: 13 Oct 2022
Price :
$50
*
At a glance
- Originator Rutgers
- Developer Biohaven Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Glutamate modulators; Glutamate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer